277 related articles for article (PubMed ID: 16723549)
21. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
[TBL] [Abstract][Full Text] [Related]
22. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
23. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
[TBL] [Abstract][Full Text] [Related]
24. Tissue and serum levofloxacin concentrations in diabetic foot infection patients.
Oberdorfer K; Swoboda S; Hamann A; Baertsch U; Kusterer K; Born B; Hoppe-Tichy T; Geiss HK; von Baum H
J Antimicrob Chemother; 2004 Oct; 54(4):836-9. PubMed ID: 15375105
[TBL] [Abstract][Full Text] [Related]
25. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
Timmers GJ; Dijstelbloem Y; Simoons-Smit AM; van Winkelhoff AJ; Touw DJ; Vandenbroucke-Grauls CM; Huijgens PC
Bone Marrow Transplant; 2004 Apr; 33(8):847-53. PubMed ID: 14755314
[TBL] [Abstract][Full Text] [Related]
28. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections.
Guillaume M; Garraffo R; Bensalem M; Janssen C; Bland S; Gaillat J; Bru JP
Med Mal Infect; 2012 Sep; 42(9):414-20. PubMed ID: 22944286
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration.
Aboubakr M
Br Poult Sci; 2012; 53(6):784-9. PubMed ID: 23398423
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
32. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic variability of extended interval tobramycin in burn patients.
Bracco D; Landry C; Dubois MJ; Eggimann P
Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
[TBL] [Abstract][Full Text] [Related]
34. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
[TBL] [Abstract][Full Text] [Related]
35. Levofloxacin pharmacokinetics in children.
Chien S; Wells TG; Blumer JL; Kearns GL; Bradley JS; Bocchini JA; Natarajan J; Maldonado S; Noel GJ
J Clin Pharmacol; 2005 Feb; 45(2):153-60. PubMed ID: 15647407
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of ofloxacin in broiler chicken.
Kalaiselvi L; Sriranjani D; Ramesh S; Sriram P; Mathuram LN
J Vet Pharmacol Ther; 2006 Jun; 29(3):185-9. PubMed ID: 16669862
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
[TBL] [Abstract][Full Text] [Related]
38. Liver tissue concentrations of levofloxacin after single intravenous administration of 500 mg for antibiotic prophylaxis in liver surgery.
Weinrich M; Scheingraber S; Stremovskaia T; Schilling MK; Kees F; Pistorius GA
Int J Antimicrob Agents; 2006 Sep; 28(3):221-5. PubMed ID: 16904875
[TBL] [Abstract][Full Text] [Related]
39. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
Zelenitsky SA; Ariano RE
J Antimicrob Chemother; 2010 Aug; 65(8):1725-32. PubMed ID: 20558470
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Czock D; Hüsig-Linde C; Langhoff A; Schöpke T; Hafer C; de Groot K; Swoboda S; Kuse E; Haller H; Fliser D; Keller F; Kielstein JT
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1263-8. PubMed ID: 17699357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
